共 46 条
- [1] Target expression, preclinical activity and mechanism of action of EM801: a novel first-in-class IgG-based BCMA T-cell bispecific antibody for the treatment of multiple myelomaONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 207 - 208Seckinger, A.Delgado, J. A.Moreno, L.Neuber, B.Grab, A. L.Lipp, S.Merino, J.Vu, M. D.Strein, K.Prosper, F.Hundemer, M.San Miguel, J.Hose, D.Paiva, B.
- [2] Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple MyelomaBLOOD, 2015, 126 (23)Seckinger, AnjaDelgado, Jose AntonioMoreno, LauraNeuber, BrigitteGrab, AnnaLipp, SusanneMerino, JuanaVu, Minh DiemStrein, KlausProsper, FelipeHundemer, MichaelMiguel, Jesus SanHose, DirkPaiva, Bruno
- [3] PRECLINICAL ACTIVITY AND MECHANISM OF ACTION OF EM801: T CELL BISPECIFIC ANTIBODY AND BCMA FOR THE TREATMENT OF MULTIPLE MYELOMAHAEMATOLOGICA, 2016, 101 : 21 - 21Narro Laura, MorenoJose Antonio, Delgado GarciaAnja, SeckingerBrigitte, NeuberAnna, GrabSusanne, LippRoncal Juana, MerinoVu Minh DiemKlaus, StreinCardoso Felipe, ProsperMichael, HundemerIzquierdo Jesus, San MiguelDirk, HoseBruno, Paiva
- [4] Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific AntibodyCANCER MANAGEMENT AND RESEARCH, 2023, 15 : 741 - 751Pan, DarrenRichter, Joshua
- [5] A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple MyelomaJOURNAL OF IMMUNOTHERAPY, 2022, 45 (02) : 78 - 88Xiong, MengshangLiu, RuoqiLei, XiaominFan, DongmeiLin, FangzhenHao, WeiYuan, XiangfeiYang, YuanyuanZhang, XiaolongYe, ZhouLu, YangZhang, YanjunWang, JianxiangXiong, Dongsheng
- [6] Development of a fully human t-cell engaging bispecific antibody for the treatment of multiple myeloma.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)Buelow, BenChoudhry, PriyaClarke, StarlynnDang, KevinDavison, LauraAldred, Shelley ForceHarris, KatherinePham, DuyPratap, PayalRangaswamy, UdayaSchellenberger, UteShah, NinaTrinklein, NathanUgamraj, HarshadWiita, ArunVan Schooten, Wim
- [7] T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagementEXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (09) : 889 - 901Heerma van Voss, Marise R.Molenaar, Remco J.Korst, Charlotte L. B. M.Bartelink, Imke H.Baglio, Serena R.Kruyswijk, Sandyde Ruijter, MaaikeZweegman, SonjaKuipers, Maria T.van de Donk, Niels W. C. J.
- [8] ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple MyelomaBLOOD, 2021, 138Stefano, SammicheliGrandclement, CamilleDehilly, EliePanagopoulou, MariaMartini, EvangeliaCastillo, RosaSuere, PerrinePouleau, BlandineEstoppey, CaroleFrei, JuliaLoyau, JeremyMonney, ThierryWood, RebeccaCroset, AmelieRubod, AlainGudi, GirishUdupa, VenkateshaGn, SunithaMenon, VinuRamussen, DanielOlsen, Jeppe KochGiovannini, RobertoChakrapani, AravindBlein, StanislasDoucey, Marie-AgnesDrake, AdamRiva, AlessandroKonto, CryilPerro, MarioMbow, Lamine
- [9] Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple MyelomaBLOOD, 2022, 140Raje, NoopurBahlis, Nizar JacquesCostello, CaitlinDholaria, BhagirathbhaiSolh, MelhemLevy, Moshe YairTomasson, Michael H.Damore, Michael A.Jiang, SiboBasu, CynthiaSkoura, AthanasiaChan, Edward M.Trudel, SuzanneJakubowiak, AndrzejChu, Michael P.Gasparetto, Cristina J.Dalovisio, Andrew P.Sebag, MichaelLesokhin, Alexander M.
- [10] A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivoLEUKEMIA, 2017, 31 (08) : 1743 - 1751Hipp, S.Tai, Y-TBlanset, D.Deegen, P.Wahl, J.Thomas, O.Rattel, B.Adam, P. J.Anderson, K. C.Friedrich, M.